Baylor College of Medicine

A study of suvecaltamide in the treatment of moderate to severe residual tremor from Parkinson's disease (H-54088)

Description

Content

A 17-Week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, multicenter study of the efficacy and safety of suvecaltamide in the treatment of moderate to severe residual tremor in participants with Parkinson's disease

The purpose of this study is to evaluate suvecaltamide in Parkinson’s disease participants. Suvecaltamide is an experimental drug, which means that the Food and Drug Administration (FDA) has not approved it for the treatment of Parkinson’s disease or any other indication.  

Contact

Rory Mahabir

Phone 1: 713–798–5989

IRB: H-54088

Status:

Active

Created:

Back to topback-to-top